Price T Rowe Associates Inc. MD Makes New Investment in Septerna, Inc. (NASDAQ:SEPN)

Price T Rowe Associates Inc. MD purchased a new position in Septerna, Inc. (NASDAQ:SEPN - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 518,588 shares of the company's stock, valued at approximately $11,877,000. Price T Rowe Associates Inc. MD owned 1.17% of Septerna as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. TRV GP V LLC acquired a new stake in Septerna during the 4th quarter valued at $142,337,000. TRV GP VI LLC purchased a new position in Septerna in the 4th quarter valued at about $72,191,000. Avoro Capital Advisors LLC acquired a new stake in shares of Septerna during the fourth quarter valued at about $25,419,000. Vanguard Group Inc. purchased a new stake in shares of Septerna during the fourth quarter worth about $22,557,000. Finally, Geode Capital Management LLC acquired a new position in shares of Septerna in the fourth quarter worth about $8,717,000.

Insider Transactions at Septerna

In related news, Director Alan Ezekowitz acquired 41,355 shares of Septerna stock in a transaction that occurred on Thursday, March 6th. The stock was acquired at an average price of $6.00 per share, with a total value of $248,130.00. Following the completion of the acquisition, the director now directly owns 104,101 shares of the company's stock, valued at $624,606. This trade represents a 65.91 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Gil M. Labrucherie acquired 5,000 shares of the firm's stock in a transaction dated Friday, February 21st. The stock was bought at an average price of $5.85 per share, with a total value of $29,250.00. Following the completion of the acquisition, the chief financial officer now directly owns 30,000 shares of the company's stock, valued at approximately $175,500. This represents a 20.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 74,346 shares of company stock valued at $439,670.

Analysts Set New Price Targets

Several equities research analysts have issued reports on SEPN shares. Cantor Fitzgerald restated an "overweight" rating and set a $50.00 price objective on shares of Septerna in a report on Tuesday, February 11th. Wells Fargo & Company cut their price target on shares of Septerna from $14.00 to $11.00 and set an "equal weight" rating on the stock in a report on Friday, March 28th.

Septerna Price Performance

NASDAQ SEPN traded down $0.18 during trading hours on Thursday, hitting $6.87. The company had a trading volume of 24,471 shares, compared to its average volume of 411,881. Septerna, Inc. has a fifty-two week low of $4.17 and a fifty-two week high of $28.99. The business has a fifty day moving average of $6.15.

Septerna (NASDAQ:SEPN - Get Free Report) last posted its earnings results on Thursday, March 27th. The company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.05. The firm had revenue of $0.21 million during the quarter, compared to the consensus estimate of $0.13 million. Equities research analysts expect that Septerna, Inc. will post -7.11 earnings per share for the current fiscal year.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.